EP4103713A4 - Agents pan-génotypiques contre les virus respiratoires et leurs méthodes d'utilisation - Google Patents

Agents pan-génotypiques contre les virus respiratoires et leurs méthodes d'utilisation Download PDF

Info

Publication number
EP4103713A4
EP4103713A4 EP21780993.8A EP21780993A EP4103713A4 EP 4103713 A4 EP4103713 A4 EP 4103713A4 EP 21780993 A EP21780993 A EP 21780993A EP 4103713 A4 EP4103713 A4 EP 4103713A4
Authority
EP
European Patent Office
Prior art keywords
genotypic
pan
methods
agent against
respiratory viruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP21780993.8A
Other languages
German (de)
English (en)
Other versions
EP4103713A1 (fr
Inventor
Jeffrey S. Glenn
Rachel Hagey Saluti
Edward A. Pham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/792,103 external-priority patent/US11339392B2/en
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to EP24198312.1A priority Critical patent/EP4464779A3/fr
Priority claimed from PCT/US2021/018025 external-priority patent/WO2021201996A1/fr
Publication of EP4103713A1 publication Critical patent/EP4103713A1/fr
Publication of EP4103713A4 publication Critical patent/EP4103713A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21780993.8A 2020-02-14 2021-02-12 Agents pan-génotypiques contre les virus respiratoires et leurs méthodes d'utilisation Withdrawn EP4103713A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP24198312.1A EP4464779A3 (fr) 2020-02-14 2021-02-12 Agents pan-génotypiques contre des virus respiratoires et leurs procédés d'utilisation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/792,103 US11339392B2 (en) 2016-03-02 2020-02-14 Pan-genotypic agents against influenza virus and methods of using the same
US202062992659P 2020-03-20 2020-03-20
PCT/US2021/018025 WO2021201996A1 (fr) 2020-02-14 2021-02-12 Agents pan-génotypiques contre les virus respiratoires et leurs méthodes d'utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP24198312.1A Division EP4464779A3 (fr) 2020-02-14 2021-02-12 Agents pan-génotypiques contre des virus respiratoires et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP4103713A1 EP4103713A1 (fr) 2022-12-21
EP4103713A4 true EP4103713A4 (fr) 2024-03-20

Family

ID=83688484

Family Applications (2)

Application Number Title Priority Date Filing Date
EP21780993.8A Withdrawn EP4103713A4 (fr) 2020-02-14 2021-02-12 Agents pan-génotypiques contre les virus respiratoires et leurs méthodes d'utilisation
EP24198312.1A Pending EP4464779A3 (fr) 2020-02-14 2021-02-12 Agents pan-génotypiques contre des virus respiratoires et leurs procédés d'utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP24198312.1A Pending EP4464779A3 (fr) 2020-02-14 2021-02-12 Agents pan-génotypiques contre des virus respiratoires et leurs procédés d'utilisation

Country Status (4)

Country Link
EP (2) EP4103713A4 (fr)
JP (2) JP2023514576A (fr)
CN (1) CN115997014A (fr)
CA (1) CA3167206A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683036B2 (en) * 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US20050182005A1 (en) * 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
CA2648132C (fr) * 2006-04-03 2019-05-28 Santaris Pharma A/S Composition pharmaceutique comprenant des oligonucleotides antisens anti-microarn
WO2013166264A2 (fr) * 2012-05-02 2013-11-07 University Of Georgia Research Foundation, Inc. Procédés pour altérer la réplication de virus
KR20200120627A (ko) * 2018-02-13 2020-10-21 도레이 카부시키가이샤 인지증 검출을 위한 키트 또는 디바이스 및 방법
GB201812334D0 (en) * 2018-07-27 2018-09-12 Univ Exeter Compositions and uses thereof
WO2021188931A1 (fr) * 2020-03-20 2021-09-23 The Board Of Trustees Of The Leland Stanford Junior University Compositions anti-coronavirus et méthodes d'utilisation de ces compositions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HAGEY RACHEL J. ET AL: "Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2", NATURE MEDICINE, vol. 28, no. 9, 18 August 2022 (2022-08-18), New York, pages 1944 - 1955, XP093126274, ISSN: 1078-8956, Retrieved from the Internet <URL:https://www.nature.com/articles/s41591-022-01908-x> DOI: 10.1038/s41591-022-01908-x *
See also references of WO2021201996A1 *
SIMONE GIANNECCHINI ET AL: "Oligonucleotides derived from the packaging signal at the 5' end of the viral PB2 segment specifically inhibit influenza virus in vitro", ARCHIVES OF VIROLOGY ; OFFICIAL JOURNAL OF THE VIROLOGY DIVISIONOF THE INTERNATIONAL UNION OF MICROBIOLOGICAL SOCIETIES, SPRINGER-VERLAG, VI, vol. 154, no. 5, 16 April 2009 (2009-04-16), pages 821 - 832, XP019722939, ISSN: 1432-8798 *
SIMONE GIANNECCHINI ET AL: "Packaging signals in the 5-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 92, no. 1, 21 June 2011 (2011-06-21), pages 64 - 72, XP028293110, ISSN: 0166-3542, [retrieved on 20110629], DOI: 10.1016/J.ANTIVIRAL.2011.06.013 *

Also Published As

Publication number Publication date
CA3167206A1 (fr) 2021-10-07
EP4464779A3 (fr) 2025-06-25
EP4464779A2 (fr) 2024-11-20
JP2023514576A (ja) 2023-04-06
CN115997014A (zh) 2023-04-21
JP2026042885A (ja) 2026-03-11
EP4103713A1 (fr) 2022-12-21

Similar Documents

Publication Publication Date Title
EP4192863A4 (fr) Molécules de liaison à il2rg et procédés d&#39;utilisation
EP4157110A4 (fr) Systèmes de cathéter d&#39;aspiration et procédés d&#39;utilisation
EP4330251A4 (fr) Agents de dégradation d&#39;egfr et méthodes d&#39;utilisation associées
EP4157259A4 (fr) Compositions de cannabinoïdes et leurs méthodes d&#39;utilisation
EP4192852A4 (fr) Molécules de liaison à l&#39;il10ra et procédés d&#39;utilisation
EP4413147A4 (fr) Variants de capside et leurs procédés d&#39;utilisation
EP4009777A4 (fr) Facteur de transcription nterf221 et ses procédés d&#39;utilisation
EP4168385A4 (fr) Analogues d&#39;hydroxynorkétamine, compositions les comprenant et leurs procédés d&#39;utilisation
EP4228491C0 (fr) Mécanismes de fixation d&#39;endoscope et méthodes d&#39;utilisation
EP4237586A4 (fr) Compositions de particules multivalentes et procédés d&#39;utilisation
EP3908293A4 (fr) Compositions de lymphocytes t activées ex vivo et leurs procédés d&#39;utilisation
EP4178568A4 (fr) Compositions et procédés pour le traitement de l&#39;apnée obstructive du sommeil (aos)
EP4142740A4 (fr) Compositions et leurs méthodes d&#39;utilisation
EP4263868A4 (fr) Nanoréseaux et leurs procédés d&#39;utilisation
EP4255503A4 (fr) Compositions et leurs procédés d&#39;utilisation
EP4192857A4 (fr) Molécules de liaison à l&#39;il10rb et leurs procédés d&#39;utilisation
EP4380626A4 (fr) Particules de virus adéno-associés et leurs procédés d&#39;utilisation
EP4240751A4 (fr) Désubiquitinases modifiées ciblant des protéines nucléaires et leurs méthodes d&#39;utilisation
EP4401747A4 (fr) Compositions dérivées de psilocybine et leurs procédés d&#39;utilisation
EP4251640A4 (fr) Vaccin à adn contre le papillomavirus humain et son procédé d&#39;utilisation
EP4240429A4 (fr) Nanoparticules thérapeutiques radiomarquées et procédés d&#39;utilisation correspondants
EP4103713A4 (fr) Agents pan-génotypiques contre les virus respiratoires et leurs méthodes d&#39;utilisation
EP4157218A4 (fr) Formulations et procédés de traitement du syndrome de détresse respiratoire aiguë, de l&#39;asthme, ou de la rhinite d&#39;origine allergique
EP4121038A4 (fr) Compositions et méthodes pour le traitement d&#39;une infection à coronavirus et d&#39;un compromis respiratoire
EP3986320A4 (fr) Guide chirurgical et procédé d&#39;utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220810

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAV Requested validation state of the european patent: fee paid

Extension state: MD

Effective date: 20220908

Extension state: MA

Effective date: 20220908

A4 Supplementary search report drawn up and despatched

Effective date: 20240216

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/16 20060101ALI20240212BHEP

Ipc: C12N 15/11 20060101AFI20240212BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240906